Between December 2024 and September 2026, several of the largest research peptide vendors closed or were targeted by federal enforcement. Peptide Sciences shut down on March 6, 2026. Science.bio closed on January 27, 2026. Amino Asylum went offline in June 2025. Eternal Peptides stopped taking orders on September 15, 2026. The owner of Paradigm Peptides was sentenced to 70 months in prison in July 2026. The timeline below lists each event with its source.
Notice: This page covers business and regulatory events only. Research peptides are not FDA-approved and not for human or animal consumption. Nothing here is legal or medical advice.
The timeline
December 10, 2024: FDA warns Swiss Chems, Summit Research Peptides and Xcel Research
FDA issued warning letters to Swisschems, Summit Research Peptides and Xcel Research. The Swisschems letter said that despite "research chemicals only" labeling, website and social media marketing showed the products were intended for human use. Swiss Chems was still operating as of September 26, 2026 (our review).
February 26, 2025: USApeptide.com warning letter
FDA warned USApeptide.com over unapproved and misbranded products.
June 2025: Amino Asylum goes offline
Amino Asylum, described as one of the largest gray-market research chemical vendors, went offline after a reported federal warehouse raid (PeptideLaws.com). We found no primary government press release on this event, so treat the details as reported.
September 8, 2025: PureRawz warning letter
FDA's letter to PureRawz concerned tianeptine products sold as "laboratory and research use only." FDA cited website and social media content as evidence of intended human use.
December 12, 2025: Pinnacle Peptides warning letter
FDA warned Pinnacle Professional Research, dba Pinnacle Peptides.
December 2025: Ohio Board of Pharmacy guidance
According to McDermott Will & Schulte, Ohio's pharmacy board said that "research purposes only" medications are unlawful for prescriber clinics and med spas to possess.
January 27, 2026: Science.bio closes
Science.bio announced it would be "permanently closing today" (forum post of the notice). Its website still shows a notice that it has "made the decision to permanently close and discontinue the sale of research products," along with a warning about impostors claiming to be affiliated with it.
March 6, 2026: Peptide Sciences shuts down
Peptide Sciences, widely described as the largest US research peptide vendor, posted: "After careful consideration, Peptide Sciences has made the decision to voluntarily shut down operations and discontinue the sale of our research products" (PeptideLaws.com; legal commentary from Lumalex Law). The company didn't publish a reason.
March 31, 2026: Gram Peptides and others warned
FDA letters dated March 31 and published April 7 went to sellers including Gram Peptides, Pink Pony Peptides (Lovega LLC), Mile High Compounds, Prime Sciences and PekCura Labs (ChemVerify summary). The Gram Peptides letter says that despite "Research Use Only" labeling, "evidence obtained from your website establishes that your products are intended to be drugs for human use."
June 17, 2026: Wholesale Peptide warning letter
FDA warned Wholesale Peptide (Brooksville, FL), citing health claims on its website.
June 2026: Alabama Medical Board notice
Per McDermott Will & Schulte, Alabama's medical board told physicians not to compound, administer or dispense "non-FDA approved or research grade peptide" to patients.
July 23-24, 2026: FDA compounding advisory committee meets on peptides
FDA's Pharmacy Compounding Advisory Committee reviewed several peptides, including BPC-157, KPV, TB-500, MOTs-C, Semax and Epitalon, for possible use in pharmacy compounding. McDermott reports the committee voted to recommend adding six peptides to the 503A bulks list. The recommendation is non-binding and doesn't cover research-use-only products. More in FDA peptide regulation 2026.
July 30, 2026: Paradigm Peptides owner sentenced
The US Attorney's Office for the Northern District of Indiana announced that Matthew Kawa was sentenced to 70 months and Jennifer Stechkober to 16 months. Both had pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead. According to the release, Paradigm sold to more than 54,000 customers from 2019 to 2024 and falsely marketed its products as domestically manufactured and tested.
August 24, 2026: Five more warning letters
FDA letters dated August 24 went to Peptide Partners, Royal Peptides, NuScience Peptides, Peak Performance Peptides and TXP Innovations, dba Tex Peptides. They were posted publicly around September 1 (JackedForums summary). The Peptide Partners letter cites website claims and the sale of injection-preparation supplies as evidence of human-use intent.
September 15, 2026: Eternal Peptides ends online ordering
According to a September 11, 2026 report, Eternal Peptides posted a banner announcing a final sale and saying all website ordering would end on September 15 at 11:59 p.m. Eastern. No reason was published. The report comes from another vendor's website, and we couldn't view the original banner.
If you were an Eternal Peptides customer, our Eternal Peptides status and alternatives page covers open orders, lookalike domains and the vendors we rate by use case.
October 10-12, 2026: Soma Chems stops taking orders
Soma Chems (somachems.com), a store that appeared in mid-2025 and also sold SARMs and products labeled as prescription drugs, marked nearly its whole catalog about 60% off in an October 10, 2026 capture. By October 12, its homepage said "Our store is no longer accepting new orders," which is what we saw when we checked on October 21. No reason was published, and we found no FDA, DOJ or court action naming it. Details and alternatives: Soma Chems status.
What the pattern shows
- The "research use only" label hasn't protected sellers. The letters we reviewed (Swisschems, PureRawz, Gram Peptides, Peptide Partners) all say labeling doesn't override marketing, product descriptions or accompanying supplies that point to human use.
- Most letters involved health claims or GLP-1-class products. The Gram Peptides and Peptide Partners letters both cite weight-management or disease claims.
- Closures often come without a reason. Peptide Sciences, Science.bio and Eternal Peptides published no formal explanation.
- Test data doesn't prevent enforcement. Vendors with substantial independent testing histories still received letters.
What this means for choosing a vendor
Any vendor can disappear quickly, so we re-check operating status and FDA records every time we update. All ten vendors on our current list were operating as of our September 26-October 13, 2026 checks. One of them, Swiss Chems, has the December 2024 warning letter above, which we disclose on its review. That's a snapshot, not a guarantee. To check a vendor yourself, search the FDA warning letter database and read our COA guide.
Related: best peptide vendors in the USA · third-party tested peptides
Looking for a replacement? See every vendor we track.
If you used one of these vendors, see our status pages with alternatives: Peptide Sciences · Science.bio · Amino Asylum · Paradigm Peptides · PureRawz · Peptide Partners
